A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer

Trial Profile

A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms LaMB; OCTG-LaMB
  • Most Recent Events

    • 01 Jan 2017 Results assessing efficacy of Lapatinib maintenance therapy published in the Journal of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint (Progression-free survival) has not been met, according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top